• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis
【2h】

Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis

机译：唑来膦酸5 mg对绝经后骨质疏松妇女骨转换标志的影响以及PINP与骨折复位的关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In patients with osteoporosis treated with antiresorptive agents, reduction in bone turnover explains much of the observed fracture risk reduction. Lower levels of bone turnover markers (BTMs) appear to be associated with a lower risk of fracture in bisphosphonate-treated patients. BTMs were measured in a subset of subjects in the HORIZON Pivotal Fracture Trial. Annual infusions of zoledronic acid 5 mg significantly reduced BTMs: median decrease of 50% for beta-C-terminal telopeptides of type 1 collagen (beta-CTX), 30% for bone alkaline phosphatase (ALP), and 56% for procollagen type 1 amino-terminal propeptide (PINP). The mean level of BTMs decreased in treated patients but remained within the premenopausal range before the next injection. The percentage of zoledronic acid-treated patients with values below the premenopausal reference range at all time points was 1.7%, 17.8%, and 19% for bone ALP, CTX, and PINP, respectively. The third injection of zoledronic acid resulted in 60% reduction of beta-CTX within 9-11 days, followed by a gradual increase, indicating the persistence of osteoclastic bone resorption. The association between changes in BTMs and fracture incidence was assessed in 1132 patients who had PINP measurements at baseline and 1 yr. There was no association between low PINP levels at 1 yr and increased fracture incidence. In summary, (1) annual injections of zoledronic acid reduced BTMs in the premenopausal range, with a significant response persisting after the third infusion; and (2) low levels of PINP were not associated with increased fracture risk.
机译：在用抗吸收剂治疗的骨质疏松症患者中，骨转换的减少可以解释许多观察到的骨折风险降低。在双膦酸盐治疗的患者中，较低的骨转换标记（BTM）水平似乎与较低的骨折风险相关。在HORIZON枢轴骨折试验中，在一部分受试者中测量了BTM。每年注射5 mg唑来膦酸可显着降低BTM：1型胶原的β-C末端端肽（beta-CTX）的中位数降低50％，骨碱性磷酸酶（ALP）的中位数降低30％，1型胶原蛋白的中位数降低56％。氨基末端前肽（PINP）。在接受治疗的患者中，BTM的平均水平下降，但仍在绝经前范围内。唑来膦酸治疗的骨ALP，CTX和PINP在所有时间点的值所占百分比均低于绝经前参考范围，分别为1.7％，17.8％和19％。唑来膦酸的第三次注射导致9- 11天内β-CTX降低60％，然后逐渐增加，表明破骨细胞骨吸收持续存在。在基线和1年时进行PINP测量的1132例患者中，评估了BTM变化与骨折发生率之间的关联。在1年时低PINP水平与骨折发生率增加之间没有关联。总之，（1）唑来膦酸的年度注射减少了绝经前范围内的BTM，在第三次输注后仍持续有明显反应； （2）PINP水平低与骨折风险增加无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号